{"id":"W4386954679","doi":"10.1016/j.cgh.2023.09.010","title":"Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)","year":2023,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"National Institutes of Health; Takeda Pharmaceutical Company; Takeda Pharmaceuticals U.S.A.","keywords":"Medicine; Adalimumab; Internal medicine; Vedolizumab; Crohn's disease; Adverse effect; Gastroenterology; Clinical endpoint; Placebo; Combination therapy; Methotrexate; Surgery; Clinical trial; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002330693,0.0002695711,0.0009630357,0.0002503757,0.0001214988,0.000352607,0.0002577011,0.0003686089,0.0009362199],"category_scores_gemma":[0.001525964,0.0001674546,0.000441364,0.0001533886,0.0002148003,0.0002495866,0.0002290352,0.0005234024,0.0001369141],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001947312,"about_ca_system_score_gemma":0.0003374781,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002458031,"about_ca_topic_score_gemma":0.0008486959,"domain_scores_codex":[0.9988742,0.0008111852,0.00005495398,0.0001005601,0.000105364,0.00005353822],"domain_scores_gemma":[0.9989712,0.0004731177,0.0003372658,0.00005437717,0.00003914841,0.0001248271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2635274,0.009086935,0.08598406,0.001750564,0.003780751,0.0004477368,0.0002965179,0.003220098,0.03917111,0.0004927959,0.002176858,0.5900651],"study_design_scores_gemma":[0.230223,0.4762916,0.2486831,0.0005897521,0.005036536,0.004787256,0.0001611363,0.01287918,0.009069601,0.001186919,0.01098523,0.0001067526],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894057,0.008940797,0.000376903,0.0002010923,0.00002572182,0.00009366136,0.00008368755,0.00002648811,0.0008459291],"genre_scores_gemma":[0.9961837,0.00172359,0.00125424,0.0001548317,0.00006050496,0.0001030029,0.0001188424,0.000003780154,0.0003975603],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002330693,"threshold_uncertainty_score":0.012326,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03671943648637237,"score_gpt":0.3299430247459963,"score_spread":0.2932235882596239,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}